Open-label add-on treatment trial of minocycline in fragile X syndrome

Carlo Paribello, Leeping Tao, Anthony Folino, Elizabeth Berry-Kravis, Michael Tranfaglia, Iryna M Ethell, Douglas W Ethell, Carlo Paribello, Leeping Tao, Anthony Folino, Elizabeth Berry-Kravis, Michael Tranfaglia, Iryna M Ethell, Douglas W Ethell

Abstract

Background: Fragile X syndrome (FXS) is a disorder characterized by a variety of disabilities, including cognitive deficits, attention-deficit/hyperactivity disorder, autism, and other socio-emotional problems. It is hypothesized that the absence of the fragile X mental retardation protein (FMRP) leads to higher levels of matrix metallo-proteinase-9 activity (MMP-9) in the brain. Minocycline inhibits MMP-9 activity, and alleviates behavioural and synapse abnormalities in fmr1 knockout mice, an established model for FXS. This open-label add-on pilot trial was conducted to evaluate safety and efficacy of minocycline in treating behavioural abnormalities that occur in humans with FXS.

Methods: Twenty individuals with FXS, ages 13-32, were randomly assigned to receive 100 mg or 200 mg of minocycline daily. Behavioural evaluations were made prior to treatment (baseline) and again 8 weeks after daily minocycline treatment. The primary outcome measure was the Aberrant Behaviour Checklist-Community Edition (ABC-C) Irritability Subscale, and the secondary outcome measures were the other ABC-C subscales, clinical global improvement scale (CGI), and the visual analog scale for behaviour (VAS). Side effects were assessed using an adverse events checklist, a complete blood count (CBC), hepatic and renal function tests, and antinuclear antibody screen (ANA), done at baseline and at 8 weeks.

Results: The ABC-C Irritability Subscale scores showed significant improvement (p < 0.001), as did the VAS (p = 0.003) and the CGI (p < 0.001). The only significant treatment-related side effects were minor diarrhea (n = 3) and seroconversion to a positive ANA (n = 2).

Conclusions: Results from this study demonstrate that minocycline provides significant functional benefits to FXS patients and that it is well-tolerated. These findings are consistent with the fmr1 knockout mouse model results, suggesting that minocycline modifies underlying neural defects that account for behavioural abnormalities. A placebo-controlled trial of minocycline in FXS is warranted.

Trial registration: ClinicalTrials.gov Open-Label Trial NCT00858689.

References

    1. Turner G, Webb T, Wake S. et al.Prevalence of fragile X syndrome. Am Med Genet. 1996;64:196–197. doi: 10.1002/(SICI)1096-8628(19960712)64:1<196::AID-AJMG35>;2-G.
    1. Berry-Kravis E. Epilepsy in fragile X syndrome. Dev Med Child Neurol. 2002;44(11):724–728. doi: 10.1111/j.1469-8749.2002.tb00277.x.
    1. Hagerman RJ. In: Fragile X Syndrome: Diagnosis, Treatment and Research. 2. Hagerman RJ, Cronister A, editor. Baltimore, MD: The Johns Hopkins University Press; 1996. The Physical and Behavioral Phenotype; pp. 3–109.
    1. Berry-Kravis E, Grossman AW, Crnic LS. et al.Fragile X syndrome. Current Pediatrics. 2002;2:316–324. doi: 10.1054/cupe.2002.0305.
    1. Verkerk AJ, Pieretti M, Sutcliffe JS. et al.Identification of a gene (FMR-I) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell. 1991;65:905–914. doi: 10.1016/0092-8674(91)90397-H.
    1. Weiler IJ, Irwin AS. et al.Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation. Proceedings of the National Academy of Sciences of the United States of America. 1997;94:5395–5400. doi: 10.1073/pnas.94.10.5395.
    1. Jin P, Warren TS. New insights into fragile X syndrome: from molecules to neurobehaviors. Trends Biochem Sci. 2003;28:152–158. doi: 10.1016/S0968-0004(03)00033-1.
    1. Beckel-Mitchener A, Greenough WT. Correlates across the structural, functional, and molecular phenotypes of fragile X syndrome. Ment Retard Dev Disabil Res Rev. 2004;10(1):53–9. doi: 10.1002/mrdd.20009.
    1. Willemsen R, Oostra AB. et al.The fragile X syndrome: from molecular genetics to neurobiology. Ment Retard Dev Disabil Res Rev. 2004;10(1):60–7. doi: 10.1002/mrdd.20010.
    1. Bear MF, Huber MK. et al.The mGluR theory of fragile X mental retardation. Trends Neurosci. 2004;27(7):370–7. doi: 10.1016/j.tins.2004.04.009.
    1. Huber KM, Roder CJ. et al.Chemical induction of mGluR5- and protein synthesis--dependent long-term depression in hippocampal area CA1. J Neurophysiol. 2001;86(1):321–5.
    1. Kaufmann WE, Abrams TM. et al.Genotype, molecular phenotype, and cognitive phenotype: correlations in fragile X syndrome. American Journal of Medical Genetics. 1999;83:286–295. doi: 10.1002/(SICI)1096-8628(19990402)83:4<286::AID-AJMG10>;2-H.
    1. Tassone F, Hagerman JR. et al.FMRP expression as a potential prognostic indicator in fragile X syndrome. American Journal of Medical Genetics. 1999;84(3):250–61. doi: 10.1002/(SICI)1096-8628(19990528)84:3<250::AID-AJMG17>;2-4.
    1. Loesch DZ, Huggins MR. et al.Phenotypic variation and FMRP levels in fragile X. Ment Retard Dev Disabil Res Rev. 2004;10(1):31–41. doi: 10.1002/mrdd.20006.
    1. Rivera SM, Menon V. et al.Functional brain activation during arithmetic processing in females with fragile X Syndrome is related to FMR1 protein expression. Hum Brain Mapp. 2002;16(4):206–18. doi: 10.1002/hbm.10048.
    1. Hessl D, Rivera MS. et al.The neuroanatomy and neuroendocrinology of fragile X syndrome. Ment Retard Dev Disabil Res Rev. 2004;10(1):17–24. doi: 10.1002/mrdd.20004.
    1. Menon V, Leroux J. et al.Frontostriatal deficits in fragile X syndrome: relation to FMR1 gene expression. Proc Natl Acad Sci USA. 2004;101(10):3615–20. doi: 10.1073/pnas.0304544101.
    1. Irwin SA, Galvez R, Greenough WT. Dendritic spine structural anomalies in fragile-X mental retardation syndrome. Cereb Cortex. 2000;10:1038–1044. doi: 10.1093/cercor/10.10.1038.
    1. Kaufmann WE, Moser HW. Dendritic anomalies in disorders associated with mental retardation. Cereb Cortex. 2000;10(10):981–991. doi: 10.1093/cercor/10.10.981. Review.
    1. Epstein J, Riley K, In: The treatment of emotional and behavioral problems. Fragile X Syndrome: Diagnosis, Treatment, and Research. Hagerman R, Hagerman P, editor. Baltimore, The Johns Hopkins University Press; 2002. pp. 339–362.
    1. Berry-Kravis E, Potanos K. Psychopharmacology in fragile X syndrome--present and future. Ment Retard Dev Disabil Res Rev. 2004;10(1):42–8. doi: 10.1002/mrdd.20007.
    1. Hagerman RJ. In: Medical follow-up and pharmacotherapy. Fragile Syndrome: Diagnosis, Treatment and Research. 3. Hagerman RJ, Hagerman PJ, editor. Baltimore, The Johns Hopkins University Press; 2002. pp. 287–338.
    1. Berry-Kravis E, Sumis A, Hervey C, Nelson M, Porges SW, Weng N, Weiler IJ, Greenough WT. Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J Dev Behav Pediatr. 2008;29:293–302. doi: 10.1097/DBP.0b013e31817dc447.
    1. Bilousova T, Rusakov DA, Ethell DW, Ethell IM. MMP-7 disrupts dendritic spines in hippocampal neurons through NMDA receptor activation. J Neurochem. 2006;97(1):44–56. doi: 10.1111/j.1471-4159.2006.03701.x.
    1. Bilousova TV, Dansie L, Ngo M, Aye J, Charles JR, Ethell DW, Ethell IM. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J Med Genet. 2009;46(2):94–102. doi: 10.1136/jmg.2008.061796.
    1. King BH, Wright MD. et al.Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2001;40(6):658–65. doi: 10.1097/00004583-200106000-00010.
    1. Aman M, Singh N. et al.The Aberrant Behavior Checklist: A behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency. 1985;89:485–491.
    1. McCracken JT, McGough J. et al.Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347(5):314–21. doi: 10.1056/NEJMoa013171.
    1. Berry-Kravis E, Krause SE, Block S. et al.AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial. J Child Adolescent Psychpharm. 2006;16:525–540. doi: 10.1089/cap.2006.16.525. Effect of CX516.
    1. Arnold LE, Vitiello B. et al.Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials. J Am Acad Child Adolesc Psychiatry. 2003;42(12):1443–50. doi: 10.1097/00004583-200312000-00011.
    1. Arnold LE, Wender HP. et al.Levoamphetamine and dextroamphetamine: comparative efficacy in the hyperkinetic syndrome. Assessment by target symptoms. Arch Gen Psychiatry. 1972;27(6):816–22.
    1. Arnold LE, Huestis DR. et al.Levoamphetamine vs dextroamphetamine in minimal brain dysfunction. Replication, time response, and differential effect by diagnostic group and family rating. Arch Gen Psychiatry. 1976;33(3):292–301.
    1. Arnold LE, Christopher J. et al.Methylphenidate vs dextroamphetamine vs caffeine in minimal/brain dysfunction: controlled comparison by placebo washout design with Bayes' analysis. Arch Gen Psychiatry. 1978;35(4):463–73.
    1. Guy W. ECDEU assessment manual for psychopharmacology (Revised) U.S. Department of Health, Education, and Welfare Publication (ADM). Rockville, MD, National Institutes of Mental Health; 1976. pp. 76–338.
    1. Abdi H. In: Encyclopedia of Measurement and Statistics. Salkind NJ, editor. Thousand Oaks, CA: Sage; 2007. Bonferroni and Šidák corrections for multiple comparisons.
    1. Farver DK. Minocycline-induced lupus. Ann Pharmacother. 1997;31:1160–3.
    1. El-Hallak M, Giani T. et al.Chronic minocycline-induced autoimmunity in children. J Pediatr. 2008;153(3):314–9. doi: 10.1016/j.jpeds.2008.03.013.
    1. Goulden V, Glass D. et al.Safety of long-term high-dose minocycline in the treatment of acne. Br J Drematol. 1996;134(4):693–5. doi: 10.1111/j.1365-2133.1996.tb06972.x.
    1. Seukeran DC, Eady EA. et al.Benefit-risk assessment of acne therapies. Lancet. 1997;349:1251–2. doi: 10.1016/S0140-6736(05)62445-2.
    1. Ethell IM, Ethell DW. Matrix metalloproteinases in brain development and remodeling: synaptic functions and targets. J Neurosci Res. 2007;85(13):2813–23. doi: 10.1002/jnr.21273. Review.
    1. Miyaoka T, Yasukawa R. et al.Minocycline as adjunctive therapy for schizophrenia: an open-label study. Clin Neuropharmacol. 2008;31(5):287–92. doi: 10.1097/WNF.0b013e3181593d45.
    1. Levkovitz Y, Mendlovich S. et al.A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry. 2010;71(2):138–49. doi: 10.4088/JCP.08m04666yel.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever